Simcere Pharmaceutical Group Limited
SMHGF
$0.6486
-$0.0621-8.74%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 9.57% | 10.44% | -10.91% | -12.26% | -12.40% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 9.57% | 10.44% | -10.91% | -12.26% | -12.40% |
| Cost of Revenue | -17.65% | -16.99% | -23.14% | -24.31% | 2.67% |
| Gross Profit | 18.59% | 19.54% | -6.99% | -8.40% | -16.46% |
| SG&A Expenses | 22.28% | 23.26% | -10.92% | -12.27% | -18.80% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -161.55% | -163.63% | 9.55% | 10.91% | 21.71% |
| Total Operating Expenses | 3.79% | 4.62% | -19.01% | -20.24% | -16.79% |
| Operating Income | 56.58% | 57.83% | 57.54% | 55.16% | 53.53% |
| Income Before Tax | 120.60% | 120.77% | -79.40% | -79.72% | -287.00% |
| Income Tax Expenses | 293.21% | 294.76% | -28.21% | -29.30% | 20.02% |
| Earnings from Continuing Operations | 117.81% | 117.95% | -80.56% | -80.86% | -277.41% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -100.00% |
| Net Income | 117.81% | 117.95% | -80.57% | -80.86% | -276.94% |
| EBIT | 56.58% | 57.83% | 57.54% | 55.16% | 53.53% |
| EBITDA | 45.78% | 46.95% | 43.19% | 41.02% | 36.29% |
| EPS Basic | 118.75% | 118.84% | -79.97% | -80.28% | -278.54% |
| Normalized Basic EPS | 54.39% | 56.14% | 48.48% | 47.76% | 72.73% |
| EPS Diluted | 118.27% | 118.36% | -79.80% | -80.10% | -278.54% |
| Normalized Diluted EPS | 54.39% | 54.39% | 48.48% | 47.76% | 72.73% |
| Average Basic Shares Outstanding | -4.79% | -4.79% | -2.55% | -2.55% | -0.60% |
| Average Diluted Shares Outstanding | -4.25% | -4.25% | -2.95% | -2.95% | -0.93% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | 6.40% | 6.40% | -- | -- | -1.60% |